Payment overview · 2025
General Payments
$3,481.31
114 reported records · 22 companies
Healthcare provider profile · identity verified
William S. Gilmer, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HOUSTON, TX · NPI 1558353417
Verified facts
What the public records show
CMS Open Payments records show William S. Gilmer, M.D. received $3,481.31 in general payments during 2025 across 114 reported records.
Lilly USA, LLC accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Botox by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $711.31 | 20.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $326.64 | 9.4% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $285.84 | 8.2% | 8 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$232.67 | 6.7% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $207.11 | 6.0% | 10 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $205.53 | 5.9% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $200.99 | 5.8% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $189.93 | 5.5% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $164.83 | 4.7% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $157.49 | 4.5% | 9 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $156.27 | 4.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $126.41 | 3.6% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $126.01 | 3.6% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $112.23 | 3.2% | 4 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $72.65 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.72 | 1.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $47.16 | 1.4% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $33.46 | 1.0% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $23.39 | 0.7% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.86 | 0.6% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.63 | 0.5% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.18 | 0.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,481.31 | 114 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $598.79 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $307.79 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $253.99 | 11 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $220.46 | 10 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $185.16 | 9 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $164.83 | 7 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $137.35 | 6 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $133.46 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $126.41 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $126.01 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $112.23 | 4 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $107.36 | 4 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $104.66 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.65 | 3 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $72.65 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $63.64 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $55.72 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $52.83 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $47.16 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $47.09 | 2 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $36.55 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $33.46 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $31.29 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $6.18 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 63 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | 13 |
| Gabapentin | Gabapentin | 53 | 14 |
| Donepezil Hcl | Donepezil Hcl | 40 | 17 |
| Levetiracetam Er | Levetiracetam | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Botox | Onabotulinumtoxina | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,481.31 · 114 records | Lilly USA, LLC | AJOVY, AMYVID, AUSTEDO XR, AVONEX, BOTOX, Briviact, CREXONT, Fintepla, INFINITY, INGREZZA, KESIMPTA, KISUNLA, Leqembi, Mavenclad, Motpoly XR, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PROCLAIM, QULIPTA, QUTENZA, REXULTI, Symbravo, TRUDHESA, TYSABRI, UBRELVY, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, XYWAV | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error